Prevalence of diabetic retinal disease (DRD) declined modestly over a 20-year period, while severe forms dropped ...

Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention ...

September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...

New post-hoc analysis of OCT scans on GCIPL and analysis of responders with improvement of 15 or 30-letter on low-contrast visual acuity (LCVA) from the Phase 2 ACUITY trial with Privosegtor, to be ...

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp ...

Damon Wayans is turning his near-death diabetes experience into a wake-up call for others, especially in at-risk communities. After a blood sugar crisis nearly put him in a coma, he overhauled his ...

TORONTO, Ontario — The use of a topical ocular nonsteroidal anti-inflammatory drug (NSAID) before and after cataract surgery leads to meaningful reductions in postoperative macular edema in patients ...

Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of ...